Pfizer Inc. PFE announced that it will be acquiring biopharmaceutical company, Anacor Pharmaceuticals, Inc. ANAC, for $99.25 per share or a total of about $5.2 billion (assuming the conversion of ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. See why.

Pfizer’s commitment to returning capital to shareholders is evident in its current annual dividend of $1.72 per share. This translates to a quarterly payment of $0.43 per share. As of May 22, 2025, ...